Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2001 2
2002 7
2003 5
2004 7
2005 20
2006 17
2007 17
2008 14
2009 14
2010 32
2011 47
2012 34
2013 43
2014 37
2015 39
2016 38
2017 39
2018 35
2019 24
2020 44
2021 39
2022 48
2023 57
2024 65
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

656 results

Results by year

Filters applied: . Clear all
Page 1
Topical and Oral Roflumilast in Dermatology: A Narrative Review.
Mansilla-Polo M, Gimeno E, Morgado-Carrasco D. Mansilla-Polo M, et al. Actas Dermosifiliogr. 2024 Mar;115(3):265-279. doi: 10.1016/j.ad.2023.09.005. Epub 2023 Sep 12. Actas Dermosifiliogr. 2024. PMID: 37709133 Free article. Review. English, Spanish.
Oral roflumilast is a phosphodiesterase-4 inhibitor approved for the prevention of exacerbations of chronic obstructive pulmonary disease and chronic bronchitis. ...Roflumilast is a promising agent to consider....
Oral roflumilast is a phosphodiesterase-4 inhibitor approved for the prevention of exacerbations of chronic obstructive pulmonary dis …
Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials.
Lebwohl MG, Kircik LH, Moore AY, Stein Gold L, Draelos ZD, Gooderham MJ, Papp KA, Bagel J, Bhatia N, Del Rosso JQ, Ferris LK, Green LJ, Hebert AA, Jones T, Kempers SE, Pariser DM, Yamauchi PS, Zirwas M, Albrecht L, Devani AR, Lomaga M, Feng A, Snyder S, Burnett P, Higham RC, Berk DR. Lebwohl MG, et al. JAMA. 2022 Sep 20;328(11):1073-1084. doi: 10.1001/jama.2022.15632. JAMA. 2022. PMID: 36125472 Free PMC article.
The incidence of treatment-emergent adverse events was 25.2% with roflumilast vs 23.5% with vehicle in trial 1 and 25.9% with roflumilast vs 18.4% with vehicle in trial 2. The incidence of serious adverse events was 0.7% with roflumilast vs 0.7% with vehicle …
The incidence of treatment-emergent adverse events was 25.2% with roflumilast vs 23.5% with vehicle in trial 1 and 25.9% with rofl …
Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial.
Blauvelt A, Draelos ZD, Stein Gold L, Alonso-Llamazares J, Bhatia N, DuBois J, Forman SB, Gooderham M, Green L, Guenthner ST, Hebert AA, Lain E, Moore AY, Papp KA, Zirwas M, Kato S, Snyder S, Krupa D, Burnett P, Berk DR, Chu DH. Blauvelt A, et al. J Am Acad Dermatol. 2024 May;90(5):986-993. doi: 10.1016/j.jaad.2023.12.065. Epub 2024 Jan 20. J Am Acad Dermatol. 2024. PMID: 38253129 Free article. Clinical Trial.
BACKGROUND: The topical phosphodiesterase 4 inhibitor roflumilast has been studied in several dermatologic conditions. OBJECTIVE: Roflumilast foam 0.3% is being investigated as a topical treatment for seborrheic dermatitis (SD). ...Safety was also assessed. RESULTS: …
BACKGROUND: The topical phosphodiesterase 4 inhibitor roflumilast has been studied in several dermatologic conditions. OBJECTIVE: …
Roflumilast.
[No authors listed] [No authors listed] Am J Health Syst Pharm. 2022 Nov 22;79(23):2086-2087. doi: 10.1093/ajhp/zxac249. Am J Health Syst Pharm. 2022. PMID: 36197808 No abstract available.
Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs.
Müller S, Maintz L, Bieber T. Müller S, et al. Allergy. 2024 Jun;79(6):1501-1515. doi: 10.1111/all.16009. Epub 2024 Jan 8. Allergy. 2024. PMID: 38186219 Review.
Among the topical therapies, tapinarof (aryl hydrocarbon receptor), ruxolitinib (JAK1/2i), delgocitinib (pan-JAKi), asivatrep (anti-transient receptor potential vanilloid), and phosphodiesterase-4-inhibitors (roflumilast, difamilast) are discussed. Among systemic therapies …
Among the topical therapies, tapinarof (aryl hydrocarbon receptor), ruxolitinib (JAK1/2i), delgocitinib (pan-JAKi), asivatrep (anti-transien …
Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial.
Martinez FJ, Calverley PM, Goehring UM, Brose M, Fabbri LM, Rabe KF. Martinez FJ, et al. Lancet. 2015 Mar 7;385(9971):857-66. doi: 10.1016/S0140-6736(14)62410-7. Epub 2015 Feb 13. Lancet. 2015. PMID: 25684586 Clinical Trial.
BACKGROUND: Roflumilast reduces exacerbations in patients with severe chronic obstructive pulmonary disease. ...Adverse events were reported by 648 (67%) of 968 patients receiving roflumilast and by 572 (59%) of 967 patients in the placebo group; adverse event-assoc …
BACKGROUND: Roflumilast reduces exacerbations in patients with severe chronic obstructive pulmonary disease. ...Adverse events were r …
Roflumilast.
Fabbri LM, Beghé B, Yasothan U, Kirkpatrick P. Fabbri LM, et al. Nat Rev Drug Discov. 2010 Oct;9(10):761-2. doi: 10.1038/nrd3276. Nat Rev Drug Discov. 2010. PMID: 20885403 No abstract available.
The Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Patients With Atopic Dermatitis: Randomized, Double-Blind, Phase 2 Proof of Concept Study.
Gooderham M, Kircik L, Zirwas M, Lee M, Kempers S, Draelos Z, Ferris L, Jones T, Saint-Cyr Proulx E, Bissonnette R, Bhatia N, Koppel R, Guenthner S, Eads K, Welgus H, Merritt C, Elias M, Navale L, Higham R, Droege M, Berk D. Gooderham M, et al. J Drugs Dermatol. 2023 Feb 1;22(2):139-147. doi: 10.36849/JDD.7295. J Drugs Dermatol. 2023. PMID: 36745371 Clinical Trial.
OBJECTIVE: To assess safety and efficacy of roflumilast cream in patients with mild to moderate AD. METHODS: In this phase 2, proof of concept trial, patients (N=136) aged ≥12 years with AD were randomized to once-daily roflumilast cream 0.15%, roflumilast …
OBJECTIVE: To assess safety and efficacy of roflumilast cream in patients with mild to moderate AD. METHODS: In this phase 2, proof o …
Topical Roflumilast for Plaque Psoriasis.
O'Toole A, Gooderham M. O'Toole A, et al. Skin Therapy Lett. 2023 Sep;28(5):1-4. Skin Therapy Lett. 2023. PMID: 37734074 Free article. Review.
Roflumilast is a highly selective phosphodiesterase-4 inhibitor for the treatment of plaque psoriasis. ...Herein, we review the safety and efficacy of roflumilast 0.3% cream, as demonstrated in clinical trials....
Roflumilast is a highly selective phosphodiesterase-4 inhibitor for the treatment of plaque psoriasis. ...Herein, we review the safet …
Roflumilast for asthma: Weighing the evidence.
Bateman ED, O'Byrne PM, Buhl R, Rabe KF. Bateman ED, et al. Pulm Pharmacol Ther. 2015 Dec;35 Suppl:S1-3. doi: 10.1016/j.pupt.2015.08.001. Epub 2015 Aug 13. Pulm Pharmacol Ther. 2015. PMID: 26278190 No abstract available.
656 results